Galecto (NASDAQ:GLTO – Get Free Report) and Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
14.2% of Galecto shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 11.9% of Galecto shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Galecto and Eterna Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galecto | N/A | -76.96% | -66.59% |
| Eterna Therapeutics | -7,513.88% | N/A | -117.48% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Galecto | 0 | 0 | 1 | 0 | 3.00 |
| Eterna Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Galecto presently has a consensus price target of $10.00, indicating a potential upside of 116.92%. Given Galecto’s stronger consensus rating and higher possible upside, research analysts plainly believe Galecto is more favorable than Eterna Therapeutics.
Volatility and Risk
Galecto has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.29, indicating that its share price is 329% more volatile than the S&P 500.
Earnings & Valuation
This table compares Galecto and Eterna Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Galecto | N/A | N/A | -$38.35 million | ($19.14) | -0.24 |
| Eterna Therapeutics | $70,000.00 | 20.26 | -$21.67 million | ($8.31) | -0.03 |
Eterna Therapeutics has higher revenue and earnings than Galecto. Galecto is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Eterna Therapeutics beats Galecto on 7 of the 13 factors compared between the two stocks.
About Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
About Eterna Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.
